. Author manuscript; available in PMC: 2022 Mar 26.

Published in final edited form as: Ann Neurol. 2008 Sep;64(3):348–352. doi: 10.1002/ana.21446

Table 3.

Combined Analysis of SNCA and APOE ε4 on β-Amyloid (Consortium to Establish a Registry for Alzheimer’s Disease) and Neurofibrillary (Braak Stage) Pathologies

				Braak Stage
SNCA A/A ^a	APOE ε4	CERAD M+F	CERAD 0	IV-VI	0-II	OR (95% CI)
+	+	44	3			11.8 (3.36–41.46)
−	+	33	1			26.6 (3.45–204.60)
+	−	54	28			1.55 (0.81–2.96)
−	−	41	33			Reference
+	+			35	3	23.3 (6.42–84.8)
−	+			26	6	8.67 (3.09–24.3)
+	−			42	25	3.36 (1.63–6.91)
−	−			21	42	Reference

rs2572324. OR = odds ratio; CI = confidence interval; CERAD = Consortium to Establish a Registry for Alzheimer’s Disease; M = moderate neuritic plaques; F = frequent neuritic plaques.